...
首页> 外文期刊>World journal of gastroenterology : >Clinical outcomes and predictive factors in oral corticosteroid-refractory active ulcerative colitis
【24h】

Clinical outcomes and predictive factors in oral corticosteroid-refractory active ulcerative colitis

机译:口服糖皮质激素难治性活动性溃疡性结肠炎的临床结局及预测因素

获取原文
获取原文并翻译 | 示例
           

摘要

AIM: To evaluate the clinical outcomes and prognostic factors after intravenous corticosteroids following oral corticosteroid failure in active ulcerative colitis patients. METHODS: Consecutive patients with moderate to severe ulcerative colitis who had been treated with a course of intravenous corticosteroids after oral corticosteroid therapy failure between January 1996 and July 2010 were recruited at Severance Hospital, Seoul, South Korea. The disease activity was measured by the Mayo score, which consists of stool frequency, rectal bleeding, mucosal appearance at flexible sigmoidoscopy, and Physician Global Assessment. We retrospectively evaluated clinical outcomes at two weeks, one month, three months, and one year after the initiation of intravenous corticosteroid therapy. Two weeks outcomes were classified as responders or non-responders. One month, three month and one year outcomes were classified into prolonged response, steroid dependency, and refractoriness. RESULTS: Our study included a total of 67 eligible patients. At two weeks, 56 (83.6%) patients responded to intravenous corticosteroids. At one month, complete remission was documented in 18 (32.1%) patients and partial remission in 26 (46.4%). Eleven patients (19.7%) were refractory to the treatment. At three months and one year, we found 37 (67.3%) and 25 (46.3%) patients in prolonged response, ten (18.2%) and 23 (42.6%) patients in corticosteroid dependency, 8 (14.5%) and 6 (11.1%) patients with no response, respectively. Total 9 patients were underwent elective proctocolectomy within 1 year. The duration of oral corticosteroid therapy (> 14 d vs ≤ 14 d, P = 0.049) and lower hemoglobin level (≤ 11.0 mg/dL vs >11.0 mg/ dL, P = 0.02) were found to be poor prognostic factors for response at two weeks. For one year outcome, univariate analysis revealed that only a partial Mayo score (≥ 6 vs <6, P = 0.057) was found to be associated with a poor response. CONCLUSION: The duration of oral corticosteroid therapy and lower hemoglobin level were strongly associated with poor outcome.
机译:目的:评估活动性溃疡性结肠炎患者口服皮质类固醇衰竭后静脉注射皮质类固醇激素后的临床结局和预后因素。方法:1996年1月至2010年7月口服糖皮质激素治疗失败后接受静脉内糖皮质激素疗程的中重度溃疡性结肠炎连续患者在韩国首尔的Severance医院招募。疾病活动性通过Mayo评分来衡量,该评分包括大便次数,直肠出血,柔性乙状结肠镜检查时的粘膜外观和Physician Global Assessment。我们回顾性评估了开始静脉注射糖皮质激素治疗后两周,一个月,三个月和一年的临床结局。两周的结果分为反应者或非反应者。 1个月,3个月和1年的结果分为长期反应,类固醇依赖和难治性。结果:我们的研究共纳入67名合格患者。两周后,有56名(83.6%)患者对静脉注射皮质类固醇激素有反应。一个月后,有18例(32.1%)患者完全缓解,有26例(46.4%)患者部分缓解。 11例患者(占19.7%)对治疗无效。在三个月零一年的时间里,我们发现延长反应的患者为37(67.3%)和25(46.3%),对皮质类固醇依赖的患者为10​​(18.2%)和23(42.6%),分别为8(14.5%)和6(11.1) %)分别无反应的患者。总共9例患者在1年内接受了选择性直肠结肠切除术。口服皮质类固醇激素治疗的持续时间(> 14 d vs≤14 d,P = 0.049)和较低的血红蛋白水平(≤11.0 mg / dL vs> 11.0 mg / dL,P = 0.02)被认为是不良反应的预后因素两个星期。对于一年的结果,单因素分析显示,仅部分Mayo评分(≥6 vs <6,P = 0.057)与不良反应相关。结论:口服糖皮质激素治疗的持续时间和较低的血红蛋白水平与不良预后密切相关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号